Skip to main content
Caplight Logo









Lumen Bioscience

Lumen Bioscience

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://www.lumen.bio/

Last Round

Series C

Extension

Oct 8, 2025

Total Funding Raised

$126.95M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Lumen Bioscience is a biotechnology company that develops oral biologic drugs and vaccine candidates using a proprietary spirulina-based platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Clean Manufacturing

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

biologic drugsspirulina platformbiomanufacturingorally delivered biologicsbio-pharmamedical countermeasuresinfectious diseasebiologic productiondrug developmentclinical-stage biotechbiotech startupsynthetic biologybioprocess optimizationantibody alternatives

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Lumen Bioscience Comparables

Compare Lumen Bioscience with similar companies based on industry and business-model similarity.

Lumen Bioscience comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Vedanta Biosciences
79%
Fzata, Inc.
78%
GAT Biosciences S.L.
78%

Lumen Bioscience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series C ExtensionOct 8, 2025
GrantOct 17, 2023
Series CJun 1, 2022
GrantJan 27, 2021
Series BSep 1, 2020
Grant
Dec 5, 2017

Key People

Founding team and executive leadership

Brian Finrow

CEO Founder

Founding Team

Lumen Bioscience Investors

Notable investors and investment history

Lumen Bioscience investors
InvestorRounds
CARB-XGrant
U.S. Department of DefenseGrant
Gates Family FoundationSeries C Extension
Gates FoundationGrant, Series C Extension
Public Health Emergency Medical Countermeasures EnterpriseGrant
WestRiver GroupSeries C Extension, Series B
U.S. Department of WarGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 25, 2026

    Monthly visitors grew 51% MoM, from 3.7K to 5.6K.

  • Mar 10, 2026

    Achieved FSCC 22000 food safety certification.

Lumen Bioscience Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Lumen Bioscience Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Lumen Bioscience's valuation, stock price, and market status.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range111
Year Founded2017
Last FundingOct 8, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?